New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AstraZeneca PLC

AZN

Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.

Revenue
+6.70%
EPS
+23.5%
Free cash flow
+1.99%
Total debt
+1.75%

Quarter to September 2026, against a year earlier

175.62 0.17 +0.10%
Market cap
$272.1B
P/E
24.6×
Fwd P/E FY26e
24.2×
Dividend yield
1.83%
F-score
9/9
ROIC
12.3%
Net debt / EBITDA
1.1×
Payout ratio
0.5×

Ratios over time FY16 to FY25

Returns on capital

ROIC was 12.2% in FY25, the highest of these ten years.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE19.9%18.0%14.0%9.3%21.1%0.4%8.6%15.6%17.6%22.8%
ROIC11.1%7.7%7.8%7.1%11.9%1.0%4.0%8.4%9.8%12.2%

Debt

Net debt is 1.13× a year’s EBITDA. Debt is 0.57× equity, against 1.36× in FY18.

Debt / equityNet debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Debt / equity1.0×1.1×1.4×1.2×1.3×0.8×0.8×0.7×0.7×0.6×
Net debt / EBITDA1.5×2.0×1.8×1.7×1.4×3.1×2.4×1.6×1.4×1.1×

Cash cycle, in days

Customers pay in 102 days, inventory is held 225 days and suppliers are paid in 868. Suppliers fund 541 days of working capital.

Cash cycleDays to pay suppliersDays to be paid
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Cash cycle−642−638−640−710−709−192−330−640−514−541
Days to pay suppliers92898495010371087556561988803868
Days to be paid7990969110110193108100102

Per share, from FY16

Since FY16, per share: free cash flow has grown 8.91% a year; revenue has grown 8.50% a year; book value has grown 10.1% a year.

Free cash flowRevenueBook value
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Free cash flow1.0×1.0×1.1×0.8×0.9×1.2×1.9×1.7×1.8×2.2×
Revenue1.0×1.0×1.0×1.0×1.1×1.5×1.6×1.6×1.9×2.1×
Book value1.0×1.0×0.8×0.9×0.9×2.1×1.8×1.9×2.0×2.4×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
26.58 28.59 34.41 63.76 386.17 41.06 95.28 44.68 28.82 19.94
Piotroski F-Score
9 6 7 7 5 7 6 4 3 6
P/S ratio
4.63 3.73 4.49 4.76 4.39 4.98 5.39 4.36 3.87 3.05
Altman Z-Score
3.52 2.77 2.69 2.66 1.94 2.31 2.25 1.90 1.80 1.66
P/FCF ratio
30.83 27.05 29.43 26.51 37.65 40.77 50.11 26.76 25.41 20.99
Altman Z″-Score (non-manufacturers)
1.80 1.30 0.90 0.65 0.97 1.03 0.52 0.92 0.85 1.12
Beneish M-Score
(2.51) (2.59) (2.58) (2.75) (2.20) (2.40) (2.59) (2.54) (2.48) (2.74)
P/Operating CF
116.08 69.36 86.44 88.08 115.85 73.70 95.56 43.27 87.10 35.77
P/B ratio
5.58 4.93 5.25 5.70 4.18 8.47 9.00 6.85 5.22 4.21
EV/Sales
5.00 4.16 4.96 5.25 5.01 5.41 5.85 4.95 4.45 3.52
EV/EBITDA
15.09 13.47 16.73 25.22 24.73 17.34 21.34 15.32 14.91 11.16
EV/FCF
33.32 30.16 32.49 29.25 43.00 44.33 54.42 30.42 29.28 24.25
Current Ratio
0.94 0.93 0.82 0.86 1.16 0.96 0.86 0.96 0.80 0.87
Net Debt/EBITDA
1.13 1.39 1.58 2.36 3.07 1.39 1.69 1.85 1.97 1.50
Debt/Equity
0.57 0.71 0.70 0.76 0.76 1.26 1.20 1.36 1.07 1.01
ROE
22.83% 17.58% 15.63% 8.61% 0.41% 21.14% 9.32% 14.05% 18.02% 19.89%
ROA
9.38% 6.86% 6.03% 3.26% 0.13% 4.99% 2.19% 3.48% 4.77% 5.71%
ROIC
12.15% 9.77% 8.45% 3.99% 1.05% 11.86% 7.06% 7.78% 7.69% 11.12%
Return on Tangible Assets
92.38% 85.66% 152.15% 68.40% 0.87% 42.68% 26.00% 32.07% 68.48% 72.08%
Average Days of Receivables
101.50 100.11 107.98 92.60 100.54 101.28 90.50 95.52 89.90 79.33
Earnings Yield
3.76% 3.50% 2.91% 1.57% 0.26% 2.44% 1.05% 2.24% 3.47% 5.02%
Free Cash Flow Yield
3.24% 3.70% 3.40% 3.77% 2.66% 2.45% 2.00% 3.74% 3.94% 4.76%
Free Cash Flow per Share
5.69 4.81 4.51 5.15 3.08 2.48 2.02 2.84 2.70 2.64
Book value per Share
31.43 26.37 25.28 23.94 27.71 11.92 11.22 11.08 13.15 13.18
Free Cash Flow
8,819.00 7,453.00 6,990.00 7,966.00 4,363.00 3,250.00 2,622.00 3,597.00 3,417.00 3,340.00
EV/EBIT
21.38 22.47 27.72 62.02 177.64 27.91 48.80 32.30 27.21 16.52
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026